Can one gene therapy cut years of eye injections? REGENXBIO’s five-year data raise the stakes
REGENXBIO reports five-year wet AMD durability and 2.5-year diabetic retinopathy data as pivotal sura-vec milestones approach.
Pharma & Biotech